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ABSTRACT/OPINION STATEMENT  
Purpose of review: The pharmacological treatment of patients with epilepsy and psychiatric 
comorbidities may sometimes represent a therapeutic challenge. This review is focused on 
the pharmacological management of patients with epilepsy and psychiatric problems in terms 
of rationalization of the antiepileptic drug (AED) treatment and the pharmacological 
management of the most clinically relevant psychiatric comorbidities, namely mood and 
anxiety disorders, psychoses and attention deficit hyperactivity disorder (ADHD). Recent 
findings: Up to 8% of patients with drug-resistant epilepsy develop treatment-emergent 
psychiatric adverse events of AED regardless of the mechanism of action of the drug and this 
is usually related to an underlying predisposition given by the previous psychiatric history 
and the involvement of mesolimbic structures. Careful history taking, periodic screening for 
mood and anxiety disorders, low starting doses and slow titration schedules can reduce the 
possibility of AED-related problems. A pragmatic checklist for the pharmacological 
management of patients with epilepsy and psychiatric disorders is presented. Summary: 
Patients should be informed of potential behavioral effects of AEDs but no drugs should be 
excluded a priori. Any psychiatric comorbidity should be addressed in the appropriate setting 
and full remission and recovery should always represent the first goal of any therapeutic 
intervention. Neurologists should be aware of side effects of major psychotropic drug classes 
in order to fully counsel their patients and other health professionals involved.   
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INTRODUCTION 
 Epilepsy is one of the most frequently encountered neurological condition with 
incidence rates, in high-income countries, ranging between 40 and 70/100000/year [1,2] 
while in low income countries the incidence is higher and up to 120/100000/year [3]. 
Prevalence studies have reported lifetime rates for epilepsy ranging between 4 and 10 /1000 
in high-income countries [4] but in selected rural areas it is reported up to 57/1000 [5]. The 
majority of people with epilepsy live a normal life but there is no doubt that the long-term 
prognosis of epilepsy is poor due to the increased morbidity and mortality [6]. This can be 
due to physical problems (e.g. fractures and injuries), comorbidities with other systemic and 
neurological diseases (e.g. stroke, diabetes) as well as psychosocial problems [7]. It is 
estimated that epilepsy accounts for the 0.5% of the total burden of diseases [8] but the 
impact of comorbidities has never been taken into account.  
The International League Against Epilepsy (ILAE) pointed out that epilepsy is a disorder of 
the brain characterized not only by recurrent seizures, but also by its neurobiological, 
cognitive, psychological and social consequences [9], emphasizing the long-term 
psychosocial issues and the high prevalence of psychiatric and behavioral problems affecting 
these patients. In general terms, psychiatric disorders show a uniformly increased prevalence 
in epilepsy as compared to the general population, with mood and anxiety disorders being the 
most frequently encountered problems among adults [10,11] while in children developmental 
issues (i.e. intellectual disabilities and autism) represent the major comorbidities [12]. In 
addition, epidemiological studies have shown that the relationship between epilepsy and 
behavioral problems is more complex than expected as not only people with epilepsy are at 
increased risk of developing psychiatric disorders but patients with psychiatric disorders are 
also at increased risk of developing epilepsy [13]. The so-called bidirectional relationship 
between epilepsy and psychiatric disorders [14] has been established not only for depression 
[15–17] but also for schizophrenia [18–20] and autism [21,22]. All these data taken together 
seem to suggest that some patients develop a complex neuropsychiatric condition 
characterized by a clinical phase dominated by psychiatric symptoms followed by the 
development of epilepsy. Whether psychiatric problems are part of a complex 
neuropsychiatric disorder, a consequence of having epilepsy or simply due to the unlucky 
occurrence of two conditions in the same patient, there is no doubt that the management of 
these patients can be quite challenging. For this reason, epileptologists need to develop 
multiple clinical skills and to organize a network of different health care professionals (i.e. 
psychiatrists, clinical psychologists, neuropsychologists, social workers and occupational 
therapists) in order to provide the best treatment for patients with epilepsy [23]. This is a 
narrative review focused on the pharmacological management of patients with epilepsy and 
psychiatric problems in terms of rationalization of the antiepileptic drug (AED) treatment and 
the pharmacological management of the most relevant, either epidemiologically or clinically, 
psychiatric conditions. 
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SHOULD PSYCHIATRIC COMORBIDITIES INFLUENCE AED CHOICE IN 
EPILEPSY?  
 It is now established that the effect of AEDs is not only restricted to the modulation of 
cortical excitability but they also modulate systems that regulate mood and behavior [24]. It 
is also established that AEDs are associated with treatment-emergent behavioral problems 
that are reported not as frequently as in epilepsy, when AEDs are used in other conditions 
such as pain, migraine or movement disorders [25]. It has been also reported that about 8% of 
patients with drug-resistant epilepsy develop treatment-emergent psychiatric adverse events 
regardless of the mechanism of action of the individual AED and this is apparently driven by 
the underlying psychiatric comorbidity [26]. Data from people with new onset epilepsy are 
more than scant, although it is reasonable to hypothesize that these problems happen less 
frequently than in patients with drug-resistant epilepsies [27].  
In general terms, the psychotropic potential of any central nervous system (CNS) agent 
correlates with the mechanism of action, for example GABAergic drugs are more sedative 
than voltage-gated channel blockers, but this does not always apply to patients with epilepsy 
as the final psychotropic effect clearly arises from the interaction between the drug and the 
epileptic brain. In fact, patients with temporal lobe epilepsy and an early onset temporolimbic 
dysfunction, as suggested by a history of febrile convulsions, have, for example, an almost 4-
time increased risk of developing depression with topiramate [28]. Still, some patients 
develop severe psychiatric reactions when their seizures are rapidly controlled or their EEG 
normalized, a phenomenon known as the Landolt’s phenomenon [29]. Finally, while some 
AEDs (i.e. valproate, carbamazepine, lamotrigine) are successfully used for the treatment of 
mood disorders outside epilepsy [24], the same AEDs may be associated with paradoxical 
mood deterioration in people with epilepsy [30,31]. A recent systematic review focusing on 
aggressive behavior, as a treatment emergent problem, shows that more than 50% of 
examined AEDs are associated with aggressive behavior as a treatment emergent adverse 
event in 1% to 10% of cases, and among identified AEDs, some of them are successfully 
used as mood stabilizers or anxiolytics outside epilepsy like valproate, lamotrigine, 
pregabalin or clobazam [31]. All these data taken together clearly suggest that, in patients 
with epilepsy, the psychiatric comorbidity represents the fertile ground on which these 
paradoxical reactions develop [30] and suggest few practical points that can help clinicians in 
managing these problems: i) the previous psychiatric history and the family psychiatric 
history should be always part of a comprehensive epileptological review; ii) all patients with 
epilepsy should be periodically screened for major psychiatric disorders; iii) all patients with 
epilepsy and their relatives should be routinely informed about the psychotropic potential of 
any AED when data are available; iv) in case of a previous psychiatric problem, even if 
currently in remission, titration rates for AEDs should be slower than those adopted in other 
patients with no previous behavioral problems (Table 1). 
The rapidity of the titration rate is an important point in order to avoid side effects and not to 
preclude the opportunity of good seizure control in patients requiring specific AEDs or 
specific AED combinations for their epilepsy syndrome. In fact, even if it is true that some 
compounds seem to be more frequently associated with behavioral problems than others 
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[24,30,32], it is also established that the rapidity of the titration schedule represents one of the 
most important variables [33,34] and this is even more important when other risk factors are 
present. A retrospective study in a large cohort of consecutive patients treated with 
topiramate shows that while a previous history of depression is associated with a 3.5-times 
increased risk of developing depression as a treatment emergent adverse event, the use of a 
rapid titration schedule on top of a previous history of depression is associated with a 23-
times increased risk [28]. In conclusion, even if it is established that some AEDs are more 
likely to be associated with treatment emergent problems than others, the way they are used 
can minimize such a risk. Patients should not have precluded the opportunity of trying an 
efficacious treatment just because they are at increased risk. It is important to explain these 
risks to patients and their relatives and to inform them that it is possible to reduce such risks 
adopting slow titration rates. 
 
PSYCHOPHARMACOLOGICAL TREATMENT IN EPILEPSY: WHAT’S THE 
DRUG OF CHOICE? 
 The optimal management of psychiatric comorbidities in epilepsy should be based on 
the identification of patients at risk, through a careful history taking, and the early 
identification of psychiatric complications, through a periodic screening. A number of 
clinical instruments have been validated in patients with epilepsy especially for the detection 
of mood and anxiety disorders [35]. The Neurological Disorders Depression Inventory for 
Epilepsy (NDDIE) [36] and the Generalized Anxiety Disorder 7 (GAD7) [37] showed to be 
very practical and user-friendly screening instruments in an outpatient setting to identify a 
major depressive episode and anxiety disorders. However, psychiatric problems are, more 
often than not, ignored and go untreated, unless they are severe enough to cause major 
disability. This is often due to the paucity or total lack of knowledge of the individual 
neurologist about psychotropic medications and how to use them [38]. During the last few 
years the ILAE has issued a number of publications regarding a pragmatic approach to these 
problems based on evidence from primary psychiatric disorders that should help clinicians in 
approaching these problems in a standardized way [39,40].  
Mood and anxiety disorders 
 Antidepressants are considered first line treatment for major depression and the 
majority of anxiety disorders in conjunction with cognitive behavioral therapy. 
Antidepressants can be classified into first generation agents such as tricyclic antidepressants 
(TCAs) and monoamine oxidase inhibitors (MAOIs) and second generation drugs, such as 
selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake 
inhibitors (SNRIs) and other antidepressants with varying mechanisms of actions [41] (Table 
2). The only double-blind trial of antidepressants in epilepsy was published more than 30 
years ago and compared nomifensine and amitriptyline with placebo [42]. Since that time, a 
number of open studies, mainly using SSRIs, in small samples of unselected patients with 
epilepsy have been published [41,43]. Despite not being controlled trials, all these studies 
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taken together show that SSRIs are safe and well tolerated in people with epilepsy. 
Historically, the effect of antidepressants on seizure threshold has represented a major 
concern for clinicians. However, this was grounded on an a priori assumption based on early 
anecdotal reports of patients developing epileptic seizures during treatment with some drugs 
[44] and EEG studies showing epileptic abnormalities during treatment with TCAs [45,46]. 
Subsequent studies clarified that the supposedly increased seizure risk was genuine for a few 
specific compounds [47] while, on the contrary, serotonin potentiation is even anticonvulsant 
[48,49]. Data from controlled trials and clinical studies in patients with depression outside 
epilepsy show that maprotiline, high doses of TCAs (>200 mg daily), especially amitriptyline 
and clomipramine, and high doses of bupropion (>450 mg) are associated with an increased 
risk of seizures [41,47]. Data regarding SSRIs show that they are not only safe in terms of 
seizure risk but there are also enough reports in patients with epilepsy regarding sertraline 
[50,51] and citalopram [52,53] to consider them first line treatment in patients with epilepsy 
and depression. Among other SSRIs, fluoxetine and fluvoxamine are generally not 
recommended mainly because of the risk of drug-drug interactions and the complex 
pharmacokinetics. In fact, both of them have an inhibitory effect on the CYP2C9 which may 
be associated with an increased risk of pharmacokinetic interactions with AEDs metabolized 
by this enzymatic pathway like phenytoin and partially valproate [41,54]. In terms of other 
potential pharmacokinetic interactions, clinicians should bear in mind that first generation 
AEDs like carbamazepine, phenytoin and barbiturates are potent inducers leading to at least 
25% reduction in plasma levels of almost all SSRIs [41]. It is still unclear whether this is 
clinically relevant, but clinical monitoring is recommended in order to achieve full remission 
from depressive symptoms. In fact, while low starting doses may be considered reasonable in 
complex patients with multiple treatments, it should be always kept in mind that this does not 
mean low target doses and full remission should always be the first goal of an antidepressant 
treatment. 
The management of side effects of antidepressants is another relevant point for clinicians. In 
fact, while neurologists may be familiar with data on seizures during antidepressant 
treatment, they are very rarely aware of the spectrum of side effects of antidepressants and 
the potential for pharmacodynamic interactions with AEDs. Hyponatraemia, weight gain, 
sexual dysfunction, extrapyramidal symptoms, bone loss and bleeding are recognized side 
effects of SSRIs and for this reason careful clinical monitoring is recommended with specific 
drug combinations: i) SSRIs-carbamazepine, oxcarbazepine and eslicarbazepine 
(hyponatraemia); ii) citalopram-valproate, carbamazepine (weight gain); iii) SSRIs-valproate 
(extrapyramidal symptoms); iv) SSRIs-carbamazepine (sexual dysfunction in males); v) 
SSRIs-carbamazepine, barbiturates, phenytoin, valproate and topiramate (bone loss); vi) 
SSRIs-valproate (bleeding) [41]. 
Psychoses 
 Psychoses represent a rare but severe problem in patients with epilepsy and should be 
always managed in a psychiatric setting. However, it is important that epileptologists are able 
to counsel patients and colleagues about the potential effect of antipsychotic drugs on seizure 
threshold and whether specific drugs should be preferred. Antipsychotic drugs are usually 
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classified into first (FGAP) and second generation drugs (SGAP). SGAPs are increasingly 
used because of their favorable profile in terms of long-term side effects with low rates of 
extrapyramidal symptoms. Data from controlled trials and open studies in patients with 
psychoses outside epilepsy show that only clozapine has a significantly increased risk of 
seizures [47]. A US case series showed that seizures during treatment with clozapine are 
clearly dose-dependent with a seizure prevalence of 1%, 2.7% and 4.4% for dosages of <300 
mg, 300-600 mg and >600 mg respectively [55,56]. EEG abnormalities are reported in up to 
5% of patients treated with clozapine [57] but it is still unknown whether these abnormalities 
represent a risk factor for clozapine-related seizures. In general terms, SGAP should be 
preferred to FGAP mainly because of the better long term tolerability but there is no evidence 
supporting the use of one drug rather than another. Risperidone and aripiprazole are often 
considered drug of choice in patients with epilepsy because of the amount of data in patients 
with autism showing no increased prevalence of seizures [58] but there is no real evidence 
favoring one drug to the other and most of the time the drug of choice is based on the 
experience of the individual clinician. For this reason, psychiatrists managing psychotic 
disorders in epilepsy should always follow guidelines of treatment outside epilepsy. In case 
clozapine is needed, slow starting doses, low titration rates and careful clinical monitoring are 
recommended.   
As already mentioned for antidepressants, psychiatrists need to be bear in mind that first 
generation AEDs (i.e. barbiturates, carbamazepine and phenytoin) induce the CYP system 
reducing the plasma levels of all antipsychotics and, for this reason, doses of the 
antipsychotic should be always adjusted according to clinical response [41] and careful 
attention is needed when the AED is discontinued to avoid antipsychotic-related toxicity [41]. 
This interaction is particularly evident for quetiapine where the combined treatment with 
carbamazepine leads to undetectable levels of the antipsychotic for doses up to 700 mg [59]. 
Regarding clozapine and olanzapine, both of them have a complex metabolism mediated by a 
number of different enzymatic pathways and for this reason a low starting dose and a slow 
titration regime should be always recommend [41,60]. In terms of potential side effects, 
clinicians should be aware of weight gain particularly with olanzapine and leukopenia with 
clozapine [41]. 
Attention deficit hyperactivity disorder 
 Attention deficit hyperactivity disorder (ADHD) has an estimated prevalence of 3.4% 
in high-income countries and shows high comorbidity rates with other neurodevelopmental 
disorders such as autism and intellectual disabilities [61]. Until recently, few outcome studies 
beyond the third decade of life were available but new epidemiological studies show that the 
long-term prognosis of ADHD is poor with only 35% of patients going into remission during 
adulthood and an increased risk of substance abuse and antisocial personality disorder, 
increased psychiatric admission, incarceration and mortality [61]. A prospective community 
based study in South West England shows that up to one third of children and adolescents 
with active epilepsy also has ADHD [12]. It is now established that ADHD is 2 to 3 times 
more frequent in epilepsy than in the general population and it is usually characterized by a 
more inattentive presentation and an equal male to female ratio [62]. A community-based 
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survey in more than 1000 adult patients with epilepsy reports ADHD-like symptoms in 1 out 
of 5 subjects and suggest a strong correlation with depression, anxiety, drug-resistance and 
poor quality of life [63].  
The majority of international guidelines include methylphenidate, atomoxetine and 
dexamphetamine as pharmacological options [64,65]. According to the NICE guidelines 
methylphenidate is the drug of choice in children with severe symptoms and/or comorbidities 
and should be always considered first line treatment in adults with ADHD [65]. Historically, 
neurologists have been reluctant to prescribe psychostimulants in patients with epilepsy but 
data from three randomized, double-blind, crossover trials show that methylphenidate 0.3-1 
mg/kg/day is well tolerated with no evidence of seizure worsening and response rates range 
between 60% and 70% [66–68]. Data on potential pharmacokinetic interactions with AEDs 
are unavailable apart from reports suggesting a potential inhibitory effect of methylphenidate 
on the CYP system [69]. For this reason, low starting doses, slow titration rates and clinical 
monitoring are advisable.  
Data about atomoxetine and amphetamines in epilepsy are mainly anecdotal [41] and for this 
reason, in case of no response to methylphenidate, parents should be informed and clinical 
monitoring is needed. All children with epilepsy and ADHD should be reviewed in a 
specialist Epilepsy Transition Service in order to fully clarify whether ADHD is in remission 
or not [70]. 
  
CONCLUSIONS 
 The pharmacological treatment of patients with epilepsy and psychiatric 
comorbidities may be quite challenging. In general terms, patients should be informed of 
potential side effects of AEDs but no drugs should be a priori excluded Careful history 
taking and periodic screening for common problems, such as mood and anxiety disorder, can 
help clinicians in identifying those at increased risk and adopt low starting doses and slow 
titration schedules of the AEDs as this practice can significantly lower the possibility of 
treatment-emergent psychiatric problems. 
For mood and anxiety disorders, citalopram and sertraline can be reasonably considered first 
line treatment bearing in mind that low starting doses do not represent low target doses and 
full remission and recovery from depression should always be the first goal of the 
antidepressant treatment. Neurologists should also be aware of major side effects of SSRIs in 
order to fully counsel their patients. Patients with epilepsy and psychotic disorders should 
have access to the same treatment strategies that are successfully used outside epilepsy 
bearing in mind the potential for pharmacokinetic interactions and the increased risk of 
seizures with clozapine. However, this option should not be precluded to patients with 
epilepsy, if clinically indicated in the specific psychotic disorder. Finally, children with 
epilepsy and ADHD should always have access to the same standard of care of children with 
ADHD outside epilepsy considering the deleterious long-term consequences of untreated 
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ADHD. If needed, methylphenidate represents a safe and effective option in children with 
epilepsy.  
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Table 1. Checklist for patients with epilepsy and psychiatric comorbidities 
 
Previous history of psychiatric disorders documented 
 
 
[] 
 
Family history of psychiatric disorders documented 
 
 
[] 
 
Screening for current psychiatric problems done (e.g. NDDIE, GAD-7) 
 
 
[] 
 
Discussed about potential treatment-emergent psychiatric problems of AEDs 
 
 
[] 
 
Low starting dose and slow titration regime for AED in place 
 
 
[] 
 
Treatment/referral for current psychiatric problem in place  
 
 
[] 
 
Potential interactions/side effects of psychotropic treatment discussed  
 
 
[] 
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Table 2. Psychotropic drug classes and main treatment issues in patients with epilepsy 
and psychiatric comorbidities. 
PSYCHOTROPIC DRUG 
CLASSES 
PSYCHOTROPIC DRUGS 
(in bold treatment of 
choice) 
TREATMENT ISSUES IN 
EPILEPSY 
ANTIDEPRESSANTS 
Reversible Inhibitors  of 
Monoamine Oxidase A 
(RIMAs) 
Moclobemide Pharmacokinetic interactions 
with inducers (barbiturates, 
CBZ, PHT). 
Increased seizure risk 
Tricyclic antidepressant 
drugs (TCAs) 
Amitriptyline, 
Clomipramine, Desipramine, 
Imipramine, Maprotiline, 
Nortriptyline, Protriptyline, 
Trimipramine 
Pharmacokinetic interactions 
with inducers (barbiturates, 
CBZ, PHT) 
Increased risk of weight gain, 
urinary retention, sexual 
dysfunction, sedation 
Increased risk of seizures for 
high doses (>200 mg) 
 
Selective Serotonin 
Reuptake Inhibitors 
(SSRIs) 
Citalopram, Escitalopram, 
Fluoxetine, Fluvoxamine, 
Paroxetine, Sertraline 
Pharmacokinetic interactions 
with inducers (barbiturates, 
CBZ, PHT) 
Increased risk of sexual 
dysfunction, hyponatraemia. 
Weight gain (citalopram) 
 
Selective Noradrenergic 
Reuptake inhibitors (NRIs) 
Reboxetine Pharmacokinetic interactions 
with inducers (barbiturates, 
CBZ, PHT) 
Norepinephrine and 
Dopamine Reuptake 
Blockers (NDRIs) 
Bupropion Pharmacokinetic interactions 
with inducers (barbiturates, 
CBZ, PHT) 
Increased seizure risk for 
high dosages (>450 mg) for 
immediate release 
formulation 
 
Dual Serotonin and 
Norepinephrine Reuptake 
Inhibitors (SNRIs) 
Duloxetine, Venlafaxine Pharmacokinetic interactions 
with inducers (barbiturates, 
CBZ, PHT) 
 
Norepinephrine and 
Specific Serotoninergic 
Antidepressants (NaSSAs) 
Mianserine, Mirtazapine Pharmacokinetic interactions 
with inducers (barbiturates, 
CBZ, PHT) 
Increased risk of sedation 
and weight gain 
 
Dual Serotonin type 2 
receptor 
Nefazodone, Trazodone Pharmacokinetic interactions 
with inducers (barbiturates, 
16 
 
Antagonists/Serotonin 
Reuptake Inhibitors 
(SARIs) 
CBZ, PHT) 
Increased risk of CBZ 
toxicity with Nefazodone 
ANTIPSYCHOTICS 
First Generation 
Antipsychotics 
Chlorpromazine, Droperidol, 
Fluphenazine, Haloperidol, 
Loxapine, Perphenazine, 
Pimozide, Prochlorperazine, 
Thiothixene, Thioridazine, 
Trifluoperazine 
Pharmacokinetic interactions 
with inducers (barbiturates, 
CBZ, PHT) 
Increased risk of sedation 
and weight gain 
 
Second Generation 
Antipsychotics 
Aripiprazole, Asenapine, 
Clozapine, IIoperidone, 
Olanzapine, Paliperidone, 
Quetiapine, Risperidone, 
Ziprasidone 
Pharmacokinetic interactions 
with inducers (barbiturates, 
CBZ, PHT) 
Increased risk of sedation 
and weight gain 
Increased risk of seizures 
(clozapine) 
Increased risk of 
agranulocitosis  (clozapine-
CBZ) 
 
PSYCHOSTIMULANTS 
Psychostimulants Methylphenidate, 
atomoxetine, 
dexamphetamine 
Pharmacokinetic interactions 
with inducers (barbiturates, 
CBZ, PHT) 
No data about atomoxetine 
and dexamphetamine 
 
 
 
 
 
 
  
